CStone Pharmaceuticals
CSPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -12.2% | -3.6% | 97.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 59% | 65.6% | 57.8% | 56.2% |
| R&D Expenses | $0 | $1 | $1 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $1 | $1 | $2 |
| Operating Income | -$0 | -$1 | -$1 | -$2 |
| % Margin | -22.5% | -125% | -189.5% | -750.6% |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$1 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$1 | -$2 |
| % Margin | -22.4% | -79.2% | -187.5% | -787.8% |
| EPS | -0.072 | -0.29 | -0.77 | -1.65 |
| % Growth | 75.3% | 62.3% | 53.3% | – |
| EPS Diluted | -0.072 | -0.29 | -0.77 | -1.65 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$1 | -$2 |
| % Margin | -6.4% | -64.1% | -176.5% | -777.6% |